18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

Aruz Mesci; Elham Ahmadi; Amr Ali; Mohammad Gouran-Savadkoohi; Evangelia Evelyn Tsakiridis; Olga-Demetra Biziotis; Tom Chow; Anil Kapoor; Monalisa Sur; Gregory R. Steinberg; Stanley Liu; Katherine Zukotynski; Theodoros Tsakiridis

Clinical and Translational Radiation Oncology (Mar 2023)

18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer

Aruz Mesci,
Elham Ahmadi,
Amr Ali,
Mohammad Gouran-Savadkoohi,
Evangelia Evelyn Tsakiridis,
Olga-Demetra Biziotis,
Tom Chow,
Anil Kapoor,
Monalisa Sur,
Gregory R. Steinberg,
Stanley Liu,
Katherine Zukotynski,
Theodoros Tsakiridis

Affiliations

Aruz Mesci: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada
Elham Ahmadi: Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada
Amr Ali: Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada
Mohammad Gouran-Savadkoohi: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada
Evangelia Evelyn Tsakiridis: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Physics, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Division of Urology, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada; Dept. of Medicine, McMaster University, Hamilton, Ontario, Canada; Dept. of Pathology, McMaster University, Hamilton, Ontario, Canada; Dept. of Radiology, McMaster University, Hamilton, Ontario, Canada; Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada; Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Olga-Demetra Biziotis: Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada
Tom Chow: Physics, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada
Anil Kapoor: Division of Urology, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada
Monalisa Sur: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Physics, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Division of Urology, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada; Dept. of Medicine, McMaster University, Hamilton, Ontario, Canada; Dept. of Pathology, McMaster University, Hamilton, Ontario, Canada; Dept. of Radiology, McMaster University, Hamilton, Ontario, Canada; Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada; Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Gregory R. Steinberg: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Physics, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Division of Urology, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada; Dept. of Medicine, McMaster University, Hamilton, Ontario, Canada; Dept. of Pathology, McMaster University, Hamilton, Ontario, Canada; Dept. of Radiology, McMaster University, Hamilton, Ontario, Canada; Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada; Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Stanley Liu: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Physics, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Division of Urology, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada; Dept. of Medicine, McMaster University, Hamilton, Ontario, Canada; Dept. of Pathology, McMaster University, Hamilton, Ontario, Canada; Dept. of Radiology, McMaster University, Hamilton, Ontario, Canada; Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada; Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Katherine Zukotynski: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Physics, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Division of Urology, McMaster University and St. Joseph’s Hospital, Hamilton, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada; Dept. of Medicine, McMaster University, Hamilton, Ontario, Canada; Dept. of Pathology, McMaster University, Hamilton, Ontario, Canada; Dept. of Radiology, McMaster University, Hamilton, Ontario, Canada; Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, Ontario, Canada; Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Theodoros Tsakiridis: Radiation Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Ontario, Canada; Dept. of Oncology, McMaster University, Hamilton, Ontario, Canada; Corresponding author at: Radiation Oncologist, Juravinski Cancer Center, Dept. of Oncology, McMaster University, Hamilton, ON L8V 5C2, Canada.

Journal volume & issue: Vol. 39
p. 100583

Abstract

Read online

Background: Prostate Specific Membrane Antigen (PSMA) – positron emission tomography (PET) guides metastasis-directed radiotherapy (MDRT) in prostate cancer (PrCa). However, its value as a treatment response assessment tool after MDRT remains unclear. Importantly, there is limited understanding of the potential of radiotherapy (RT) to alter PSMA gene (folate hydrolase 1; FOLH1) expression. Methodology: We reviewed a series of 11 men with oligo-metastatic PrCa (25 metastasis sites) treated with MDRT before re-staging with 18F-DCFPyL (PSMA) PET upon secondary recurrence. Acute effects of RT on PSMA protein and mRNA levels were examined with qPCR and immunoblotting in human wild-type androgen-sensitive (LNCap), castrate-resistant (22RV1) and castrate-resistant neuroendocrine (PC3 and DU145) PrCa cell lines. Xenograft tumors were analyzed with immunohistochemistry. Further, we examined PSMA expression in untreated and irradiated radio-resistant (RR) 22RV1 (22RV1-RR) and DU145 (DU145-RR) cells and xenografts selected for survival after high-dose RT. Results: The majority of MDRT-treated lesions showed lack of PSMA-PET/CT avidity, suggesting treatment response even after low biological effective dose (BED) MDRT. We observed similar high degree of heterogeneity of PSMA expression in both human specimens and in xenograft tumors. PSMA was highly expressed in LNCap and 22RV1 cells and tumors but not in the neuroendocrine PC3 and DU145 models. Single fraction RT caused detectable reduction in PSMA protein but not in mRNA levels in LNCap cells and did not significantly alter PSMA protein or mRNA levels in tissue culture or xenografts of the other cell lines. However, radio-resistant 22RV1-RR cells and tumors demonstrated marked decrease of PSMA transcript and protein expression over their parental counterparts. Conclusions: PSMA-PET may be a promising tool to assess RT response in oligo-metastatic PrCa. However, future systematic investigation of this concept should recognize the high degree of heterogeneity of PSMA expression within prostate tumors and the risk for loss of PSMA expression in tumor surviving curative courses of RT.

Published in Clinical and Translational Radiation Oncology

ISSN: 2405-6308 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/clinical-and-translational-radiation-oncology

About the journal

Abstract

Keywords